87 results on '"Gendzekhadze, K."'
Search Results
2. P108 Utilization of HistoTrac® module for managing donor search in a high-volume hematopoietic cell transplant program
- Author
-
Bamert, R., Richetts, J., Fulton, A., Agustin-Rumbaoa, M., Mendez, C., Palmer, L., Al Malki, M., Gendzekhadze, K., and Townshend, S.
- Published
- 2023
- Full Text
- View/download PDF
3. P527 We have seen it all: Hemi-, homo-, hetero- and now tri-zygous HLA-DR – Unique case described in a healthy donor
- Author
-
Peton, B., Bibee, K., Choi, R., Garcia-Gomez, J., Gendzekhadze, K., and Al Malki, M.
- Published
- 2023
- Full Text
- View/download PDF
4. P524 Defining novel HLA serological specificities using a large clinical data of single antigen bead assay
- Author
-
Osoegawa, K., Wang, L., Fernández-Viña, M., Gendzekhadze, K., and Murphey, C.
- Published
- 2023
- Full Text
- View/download PDF
5. P119 Invisible ink: Some markers for copy-neutral loss-of-heterozygosity chimerism are only detectable when they disappear
- Author
-
Carter, M., Garcia-Gomez, J., Al Malki, M., Gendzekhadze, K., Nelson, W., Pyo, C., and Geraghty, D.
- Published
- 2023
- Full Text
- View/download PDF
6. Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV–HCV co-infected individuals
- Author
-
Legrand, N, primary, David, G, additional, Rodallec, A, additional, Gaultier, A, additional, Salmon, D, additional, Cesbron, A, additional, Wittkop, L, additional, Raffi, F, additional, Gendzekhadze, K, additional, Retière, C, additional, Allavena, C, additional, and Gagne, K, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Human leukocyte antigen class I and MICA haplotypes in a multicase family with Cladophialophora carrionii chromoblastomycosis
- Author
-
Naranjo, F., Márquez, I., Gendzekhadze, K., Zhang, S., Fernández-Mestre, M., Yegres, F., Richard-Yegres, N., Navas, T., Montagnani, S., Ogando, V., and Layrisse, Z.
- Published
- 2006
8. TNF-α-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients
- Author
-
Fernández-Mestre, M. T., Gendzekhadze, K., Rivas-Vetencourt, P., and Layrisse, Z.
- Published
- 2004
9. Colonia Tovar: the history of a semi-isolated Venezuelan population of German ancestry described by HLA Class I genes
- Author
-
Gendzekhadze, K., Montagnani, S., Ogando, V., Balbas, O., Mendez-Castellano, H., and Layrisse, Z.
- Published
- 2003
10. Therapy-Related Myelodysplasia: Somatic Mutations and Allogeneic Hematopoietic Cell Transplantation Outcomes
- Author
-
Nakamura, R., primary, Pham, A., additional, Gendzekhadze, K., additional, Min, L., additional, Pullarkat, V., additional, Al Malki, M., additional, O Donnell, M., additional, Cao, T., additional, Stein, A., additional, Khaled, S., additional, Ali, H., additional, Senitzer, D., additional, Michelle Afkhami, M.A., additional, Aoun, P., additional, Murata-Collins, J., additional, Forman, S., additional, Palmer, J., additional, Marcucci, G., additional, Pillai, R., additional, and Aldoss, I., additional
- Published
- 2017
- Full Text
- View/download PDF
11. 63 - Therapy-Related Myelodysplasia: Somatic Mutations and Allogeneic Hematopoietic Cell Transplantation Outcomes
- Author
-
Nakamura, R., Pham, A., Gendzekhadze, K., Min, L., Pullarkat, V., Al Malki, M., O Donnell, M., Cao, T., Stein, A., Khaled, S., Ali, H., Senitzer, D., Michelle Afkhami, M.A., Aoun, P., Murata-Collins, J., Forman, S., Palmer, J., Marcucci, G., Pillai, R., and Aldoss, I.
- Published
- 2017
- Full Text
- View/download PDF
12. Multiaggregate hepatocyte (HP) spheroids in the hepato-cellular transplant: structural, functional and metabolic characterization
- Author
-
Carrillo, G, Gendzekhadze, K, Ruı́z, M.E, Ruı́z, M-C, Ramı́rez, C.D, Martinez, A, Acevedo, C.H, Zerpa, M, and Rivas-Vetencourt, P.A
- Published
- 2001
- Full Text
- View/download PDF
13. IMMUNOGENETIC FACTORS INFLUENCING CLINICAL COURSE OF HCV INFECTION (REVIEW).
- Author
-
Kamkamidze, G., Butsashvili, M., and Gendzekhadze, K.
- Published
- 2016
14. Is Kir Haplotype Matching Important?
- Author
-
Gendzekhadze, K., primary, Oki, A., additional, Shen, Y., additional, Palmer, J., additional, Nademanee, A., additional, Nakamura, R., additional, Forman, S., additional, and Senitzer, D., additional
- Published
- 2012
- Full Text
- View/download PDF
15. The novel HLA-B*15:180 allele appears to be a recombinant B*08/B*15 allele
- Author
-
Gendzekhadze, K., primary, Goto, R. M., additional, Gaidulis, L., additional, Miller, M. M., additional, and Senitzer, D., additional
- Published
- 2010
- Full Text
- View/download PDF
16. HLA-A, -B and -Cw allele frequencies in two populations from Venezuela
- Author
-
Gendzekhadze, K., Montagnani, S., Ogo, V., Fernàndez-Mestre, M., Balbas, O., and Layrisse, Z.
- Published
- 2004
- Full Text
- View/download PDF
17. EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY
- Author
-
Vago, L., Toffalori, C., Ahci, M., Lange, V., Lang, K., Todaro, S., Stempelmann, K., Heinold, A., Stoelzel, F., Waterhouse, M., Claus, R., Gendzekhadze, K., Onozawa, M., Devillier, R., Tang, R., Ulman, M., Kwon, M., Gojo, I., Ruggeri, L., Imovilli, A., Facchini, L., Lazarevic, D., Stanghellini, M. T. Lupo, Peccatori, J., Steckel, N. K., Horn, P. A., Picardi, A., Manetta, S., Pinana, J. L., Sanz, J., Martinez Laperche, C., Ciurea, S., Luznik, L., Velardi, A., Arcese, W., Sanz, G., Pini, M., Bruno, B., Kobbe, G., Al Malki, M., Teshima, T., Kroeger, N., Finke, J., Nagler, A., Didier Blaise, Mohty, M., Bornhaeuser, M., Beelen, D. W., Schmidt, A., Ciceri, F., and Fleischhauer, K.
18. A new strategy for systematically classifying HLA alleles into serological specificities: Update and refinement.
- Author
-
Osoegawa K, Yim K, Jeracki M, Nguyen TN, Wang L, Cho A, David R, Son J, Mankey A, Marsh SGE, Gendzekhadze K, Murphey C, and Fernández Viňa MA
- Subjects
- Humans, Epitopes immunology, Flow Cytometry methods, Isoantibodies immunology, Isoantibodies blood, Alleles, Histocompatibility Testing methods, HLA Antigens genetics, HLA Antigens immunology
- Abstract
HLA antigens were historically defined according to the unique reactivity pattern of cells expressing HLA molecules with distinctive clusters of allo-antisera and/or monoclonal antibodies. Subsequently, amino acid residues determining epitopes (DEP) in the HLA molecule were correlated with reactivity patterns. In current clinical practice, the presence of allo-antibodies is assessed using Luminex-based solid phase single antigen bead (SAB) assays for transplantation. Recently, novel antigens were proposed for HLA molecules with DEP patterns that do not match any serologically defined antigens recognised by the WHO Nomenclature Committee. To validate the antigens, mean fluorescence intensity values of SABs tested on >13,000 patients' sera were extracted from clinical databases and analysed by scatter plots using a linear regression model. We found that when two proteins were considered as the same antigen in the original study, for example, HLA-A*02:01 and -A*02:06, their correlation ranked among the highest values at each locus. In contrast, discrete asymmetric outliers were observed when there were different antigens, for example, HLA-A*30:01 and -A*30:02, allowing validation and confirmation of 20 novel antigens for HLA-A, -B, -C and -DR. The outliers were confirmed to be true or false by flow cytometric crossmatches. In addition to the previously defined residues for antigen assignments, findings suggest that further distinction should be made for common antigens by including the substitutions at residue 67 of HLA-B, 67 and 74 of -DR. These serologic analyses can be applied systematically to identify and confirm novel antigens. These developments will lead to designing optimal SAB panels and further improving virtual donor-specific antibodies assessment., (© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
19. The 18th International HLA & Immunogenetics workshop project report: Creating fully representative MHC reference haplotypes.
- Author
-
Pollock NR, Farias TDJ, Kichula KM, Sauter J, Scholz S, Nii-Trebi NI, Khor SS, Tokunaga K, Voorter CE, Groeneweg M, Augusto DG, Arrieta-Bolaños E, Mayor NP, Edinur HA, ElGhazali G, Issler HC, Petzl-Erler ML, Oksenberg JR, Marin WM, Hollenbach JA, Gendzekhadze K, Cita R, Stelet V, Rajalingam R, Koskela S, Clancy J, Chatzistamatiou T, Houwaart T, Kulski J, Guethlein LA, Parham P, Schmidt AH, Dilthey A, and Norman PJ
- Subjects
- Humans, Histocompatibility Testing, Major Histocompatibility Complex genetics, Haplotypes, HLA Antigens genetics, Immunogenetics methods
- Published
- 2024
- Full Text
- View/download PDF
20. Multifactorial determinants of NK cell repertoire organization: insights into age, sex, KIR genotype, HLA typing, and CMV influence.
- Author
-
Ferron E, David G, Willem C, Legrand N, Salameh P, Anquetil L, Walencik A, Gendzekhadze K, Gagne K, and Retière C
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Sex Factors, Age Factors, CD57 Antigens, Histocompatibility Testing, Young Adult, NK Cell Lectin-Like Receptor Subfamily C genetics, HLA Antigens genetics, HLA Antigens immunology, Aged, Receptors, KIR3DL1 genetics, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Cytomegalovirus Infections immunology, Cytomegalovirus Infections genetics, Cytomegalovirus immunology, Genotype, Receptors, KIR genetics
- Abstract
Introduction: Polymorphisms in the KIR and HLA genes contribute to the diversity of the NK cell repertoire. Extrinsic factors also play a role in modifying this repertoire. The best example is cytomegalovirus, which promotes the expansion of memory-like NK cells. However, the mechanisms governing this phenotypic structure are poorly understood. Furthermore, the influence of age and sex has been understudied., Methods: In this study, we examined these parameters in a cohort of 200 healthy volunteer blood donors, focusing on the major inhibitory KIR receptors and CD94/NKG2A, as well as the differentiation marker CD57 and the memory-like population marker NKG2C. Flow cytometry and two joint analyses, unsupervised and semi-supervised, helped define the impact of various intrinsic and extrinsic markers on the phenotypic structure of the NK cell repertoire., Results: In the KIR NK cell compartment, the KIR3DL1 gene is crucial, as unexpressed alleles lead to a repertoire dominated by KIR2D interacting only with HLA-C ligands, whereas an expressed KIR3DL1 gene allows for a greater diversity of NK cell subpopulations interacting with all HLA class I ligands. KIR2DL2 subsequently favors the KIR2D NK cell repertoire specific to C1/C2 ligands, whereas its absence promotes the expression of KIR2DL1 specific to the C2 ligand. The C2C2Bw4+ environment, marked by strong -21T motifs, favors the expansion of the NK cell population expressing only CD57, whereas the absence of HLA-A3/A11 ligands favors the population expressing only NKG2A, a population highly represented within the repertoire. The AA KIR genotype favors NK cell populations without KIR and NKG2A receptors, whereas the KIR B+ genotypes favor populations expressing KIR and NKG2A. Interestingly, we showed that women have a repertoire enriched in CD57- NK cell populations, while men have more CD57+ NK cell subpopulations., Discussion: Overall, our data demonstrate that the phenotypic structure of the NK cell repertoire follows well-defined genetic rules and that immunological history, sex, and age contribute to shaping this NK cell diversity. These elements can contribute to the better selection of hematopoietic stem cell donors and the definition of allogeneic NK cells for cell engineering in NK cell-based immunotherapy approaches.cters are displayed correctly., Competing Interests: The authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest., (Copyright © 2024 Ferron, David, Willem, Legrand, Salameh, Anquetil, Walencik, Gendzekhadze, Gagne and Retière.)
- Published
- 2024
- Full Text
- View/download PDF
21. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
- Author
-
Dickter JK, Aribi A, Cardoso AA, Gianella S, Gendzekhadze K, Li S, Feng Y, Chaillon A, Laird GM, Browning DL, Ross JA, Nanayakkara DD, Puing A, Stan R, Lai LL, Chang S, Kidambi TD, Thomas S, Al Malki MM, Nakamura R, Alvarnas J, Taplitz RA, Dadwal SS, Forman SJ, and Zaia JA
- Subjects
- Humans, Causality, Remission Induction, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, HIV Seropositivity, HIV-1, HIV Infections therapy, HIV Infections virology
- Published
- 2024
- Full Text
- View/download PDF
22. Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells.
- Author
-
Peton B, Taniguchi M, Mangiola M, Al Malki MM, and Gendzekhadze K
- Subjects
- Humans, Alleles, HLA-DP Antigens, Epitopes, Lymphocytes, Antibodies, Monoclonal, Peripheral Blood Stem Cells
- Abstract
HLA Class I and II expression are known to differ locus-to-locus, however, HLA expression on the cell-surface is frequently reported as the total amount of HLA Class I or II antigens. This is despite evidence that indicates the differential expression of HLA can influence patient outcomes post-transplantation. Although numerous commercially available HLA monoclonal antibodies (mAbs) exist to characterize HLA expression, there is currently a lack of detailed information regarding their reactivities to HLA specificities. The specificities of locus-specific HLA mAbs (nine Class I and four Class II mAbs) were evaluated by two solid-phase Luminex single antigen bead assays. The reactivity patterns of these mAbs were then confirmed by flow cytometry using lymphocytes and PBSCs (peripheral blood stem cells). Out of the 13 HLA mAbs tested, only four (one Class I and three Class II mAbs) displayed intra-locus reactivity without also reacting to inter-locus specificities. Epitope analysis revealed the presence of shared epitopes across numerous HLA loci, explaining much of the observed inter-locus reactivity. The specificity of the HLA mAbs seen in solid-phase assays was confirmed against PBSCs and lymphocytes by flow cytometry. Using this method, we observed differences in the cell surface expression of HLA-C, HLA-DR, HLA-DQ, and HLA-DP between PBSCs and lymphocytes. Our results emphasize the need to characterize the reactivity patterns of HLA mAbs using solid-phase assays before their use on cells. Through understanding the reactivity of these HLA mAbs, the cellular expression of HLA can be more accurately assessed in downstream assays., (© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
23. Seventy-five years of service: an overview of the College of American Pathologists' proficiency testing program in histocompatibility and identity testing.
- Author
-
Sullivan HC, Gandhi MJ, Gaitonde S, Narasimhan R, Gendzekhadze K, Pandey S, Roby RK, Maha GC, Kaur H, Schiller JJ, McDowell J, Smith M, Liu C, and Morris GP
- Abstract
The Histocompatibility and Identity Testing Committee offers an overview of the College of American Pathologists' (CAP) Proficiency Testing (PT) program, commemorating its significant 75th anniversary in 2024. The CAP PT program has undergone significant growth and evolution over the years, ultimately achieving Centers for Medicare and Medicaid Services approval. In 1979, CAP's partnership with the American Association for Clinical Histocompatibility Testing marked a pivotal moment, leading to the creation of the first proficiency testing survey in 1980. This laid the foundation for various PT programs managed by the CAP Histocompatibility and Identity Testing Committee, including HLA antibody testing, HLA molecular typing, engraftment monitoring, parentage/relationship testing, HLA disease associations and drug risk, and HLA-B27 typing. Each program's distinctive considerations, grading methodologies, and future prospects are detailed here, highlighting the continual evolution of histocompatibility and identity testing PT to support emerging technologies and evolving laboratory practices in the field., Competing Interests: Author GcM was employed by the Laboratory Corporation of America Holdings. Author JS was employed by the Versiti Wisconsin Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Sullivan, Gandhi, Gaitonde, Narasimhan, Gendzekhadze, Pandey, Roby, Maha, Kaur, Schiller, McDowell, Smith, Liu and Morris.)
- Published
- 2023
- Full Text
- View/download PDF
24. Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia.
- Author
-
Aldoss I, Tizro P, Bedi D, Mangan JK, Clark MC, Spencer D, Song JY, Cherian S, Pillai R, Kim Y, Mahajan N, Gendzekhadze K, James M, Jacobs K, Davidson-Moncada J, Forman SJ, Wang HY, and Afkhami M
- Subjects
- Humans, Cell Lineage, Immunotherapy, Adoptive, T-Lymphocytes, Cell- and Tissue-Based Therapy, Antigens, CD19, Receptors, Chimeric Antigen genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapy
- Published
- 2023
- Full Text
- View/download PDF
25. Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation.
- Author
-
Legrand N, Salameh P, Jullien M, Chevallier P, Ferron E, David G, Devilder MC, Willem C, Gendzekhadze K, Parham P, Retière C, and Gagne K
- Abstract
KIR3DL1 alleles are expressed at different levels on the natural killer (NK) cell surface. In particular, the non-expressed KIR3DL1*004 allele appears to be common in Caucasian populations. However, the overall distribution of non-expressed KIR3DL1 alleles and their clinical relevance after T-replete haploidentical hematopoietic stem cell transplantation (hHSCT) with post-transplant cyclophosphamide remain poorly documented in European populations. In a cohort of French blood donors (N = 278), we compared the distribution of expressed and non-expressed KIR3DL1 alleles using next-generation sequencing (NGS) technology combined with multi-color flow cytometry. We confirmed the predominance of the non-expressed KIR3DL1*004 allele. Using allele-specific constructs, the phenotype and function of the uncommon KIR3DL1*019 allotype were characterized using the Jurkat T cell line and NKL transfectants. Although poorly expressed on the NK cell surface, KIR3DL1*019 is retained within NK cells, where it induces missing self-recognition of the Bw4 epitope. Transposing our in vitro observations to a cohort of hHSCT patients (N = 186) led us to observe that non-expressed KIR3DL1 HSC grafts increased the incidence of relapse in patients with myeloid diseases. Non-expressed KIR3DL1 alleles could, therefore, influence the outcome of hHSCT.
- Published
- 2023
- Full Text
- View/download PDF
26. Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis.
- Author
-
La Rosa C, Aldoss I, Park Y, Yang D, Zhou Q, Gendzekhadze K, Kaltcheva T, Rida W, Dempsey S, Arslan S, Artz A, Ball B, Nikolaenko L, Pullarkat VA, Nakamura R, and Diamond DJ
- Subjects
- Adult, Humans, Cytomegalovirus, CD8-Positive T-Lymphocytes, Antiviral Agents therapeutic use, Vaccination, Hematopoietic Stem Cell Transplantation adverse effects, Vaccinia drug therapy, Vaccinia etiology, Cytomegalovirus Infections prevention & control
- Abstract
To enhance protective cytomegalovirus (CMV)-specific T cells in immunosuppressed recipients of an allogeneic hematopoietic cell transplant (HCT), we evaluated post-HCT impact of vaccinating healthy HCT donors with Triplex. Triplex is a viral vectored recombinant vaccine expressing three immunodominant CMV antigens. The vector is modified vaccinia Ankara (MVA), an attenuated, non-replicating poxvirus derived from the vaccinia virus strain Ankara. It demonstrated tolerability and immunogenicity in healthy adults and HCT recipients, in whom it also reduced CMV reactivation. Here, we report feasibility, safety, and immunological outcomes of a pilot phase 1 trial (NCT03560752 at ClinicalTrials.gov) including 17 CMV-seropositive recipients who received an HCT from a matched related donor (MRD) vaccinated with 5.1 × 10
8 pfu/ml of Triplex before cell harvest (median 15, range 11-28 days). Donor and recipient pairs who committed to participation in the trial resulted in exceptional adherence to the protocol. Triplex was well-tolerated with limited adverse events in donors and recipients, who all engrafted with full donor chimerism. On day 28 post-HCT, levels of functional vaccinia- and CMV-specific CD137+ CD8+ T cells were significantly higher (p < .0001 and p = .0174, respectively) in recipients of Triplex vaccinated MRD than unvaccinated MRD (control cohort). Predominantly, central and effector memory CMV-specific T-cell responses continued to steadily expand through 1-year follow-up. CMV viremia requiring antivirals developed in three recipients (18%). In summary, this novel approach represents a promising strategy applicable to different HCT settings for limiting the use of antiviral prophylaxis, which can impair and delay CMV-specific immunity, leading to CMV reactivation requiring treatment., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)- Published
- 2023
- Full Text
- View/download PDF
27. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
- Author
-
La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, Ly M, Li J, Kaltcheva T, Ortega Francisco S, Gutierrez MA, Ali H, Otoukesh S, Amanam I, Salhotra A, Pullarkat VA, Aldoss I, Rosenzweig M, Aribi AM, Stein AS, Marcucci G, Dadwal SS, Nakamura R, Forman SJ, Al Malki MM, and Diamond DJ
- Subjects
- Humans, SARS-CoV-2, Tissue Donors, Transplant Recipients, COVID-19 Vaccines, COVID-19, Hematopoietic Stem Cell Transplantation, T-Lymphocytes immunology
- Abstract
In the current post-pandemic era, recipients of an allogeneic hematopoietic stem cell transplant (HCT) deserve special attention. In these vulnerable patients, vaccine effectiveness is reduced by post-transplant immune-suppressive therapy; consequently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is often associated with elevated morbidity and mortality. Characterizing SARS-CoV-2 adaptive immunity transfer from immune donors to HCT recipients in the context of immunosuppression will help identify optimal timing and vaccination strategies that can provide adequate protection to HCT recipients against infection with evolving SARS-CoV-2 variants. We performed a prospective observational study (NCT04666025 at ClinicalTrials.gov) to longitudinally monitor the transfer of SARS-CoV-2-specific antiviral immunity from HCT donors, who were either vaccinated or had a history of COVID-19, to their recipients via T-cell replete graft. Levels, function, and quality of SARS-CoV-2-specific immune responses were longitudinally analyzed up to 6 months post-HCT in 14 matched unrelated donor/recipients and four haploidentical donor/recipient pairs. A markedly skewed donor-derived SARS-CoV-2 CD4 T-cell response was measurable in 15 (83%) recipients. It showed a polarized Th1 functional profile, with the prevalence of central memory phenotype subsets. SARS-CoV-2-specific IFN-γ was detectable throughout the observation period, including early post-transplant (day +30). Functionally experienced SARS-CoV-2 Th1-type T cells promptly expanded in two recipients at the time of post-HCT vaccination and in two others who were infected and survived post-transplant COVID-19 infection. Our data suggest that donor-derived SARS-CoV-2 T-cell responses are functional in immunosuppressed recipients and may play a critical role in post-HCT vaccine response and protection from the fatal disease., Clinical Trial Registration: clinicaltrials.gov, identifier NCT04666025., Competing Interests: CLR received consulting fees and research funding from Helocyte Inc. DJD received consulting fees, patent royalties, research funding, and fees for serving on the advisory board of Helocyte Inc. In addition, DJD has two patents, 8,580,276 and 9,675,689, that are licensed to Helocyte. DJD and FC are co-inventors of the Patent Cooperation Treaty PCT application that covers the development of a COVID-19 vaccine PCT/US2021/032821 licensed to GeoVax Labs Inc. DD receives consulting fees and research support from GeoVax Labs Inc. RN is a consultant for Omeros, Bluebird, Viracor Eurofins, Magenta Therapeutics, Kadmon, and Napajen Pharma; received research funding from Helocyte, Miyarisan Pharmaceutical; and receives travel, accommodations, expenses from Kyowa Hakko Kirin, Alexion Pharmaceuticals. SD is a consultant for Merck, Allovir, and Aseptiscope; an Advisory board for Merck and Aseptiscope; an investigator for Allovir, Merck, Ansun, Gilead, Janssen, Shire/Takeda; and on the speaker’s bureau of Merck, Takeda, and Astellas. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 La Rosa, Chiuppesi, Park, Zhou, Yang, Gendzekhadze, Ly, Li, Kaltcheva, Ortega Francisco, Gutierrez, Ali, Otoukesh, Amanam, Salhotra, Pullarkat, Aldoss, Rosenzweig, Aribi, Stein, Marcucci, Dadwal, Nakamura, Forman, Al Malki and Diamond.)
- Published
- 2023
- Full Text
- View/download PDF
28. Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients.
- Author
-
La Rosa C, Chiuppesi F, Park Y, Gendzekhadze K, Zhou Q, Faircloth K, Kaltcheva T, Johnson D, Ortega Francisco S, Amanam I, Otoukesh S, Pullarkat VA, Nakamura R, Diamond DJ, Forman SJ, and Al Malki MM
- Subjects
- Adoptive Transfer, Humans, SARS-CoV-2, COVID-19, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation
- Published
- 2022
- Full Text
- View/download PDF
29. Identification of the Novel HLA-A*24:518N Null Allele and Evaluation of its Cell Surface Expression on Lymphocytes.
- Author
-
Peton BP, Taniguchi M, Garcia-Gomez JF, Zeng B, Oki A, Banuelos N, Nelson WC, Abou-Taleb R, Al Malki MM, and Gendzekhadze K
- Subjects
- Alleles, Exons, HLA-A Antigens, Lymphocytes
- Abstract
Competing Interests: The authors declare no conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF
30. Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
- Author
-
Carter M, Taniguchi M, Yang D, Arslan S, Shouse G, Ali H, Karras N, Gendzekhadze K, and Al Malki MM
- Subjects
- Cyclophosphamide therapeutic use, Humans, Tissue Donors, Transplantation Conditioning, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Published
- 2022
- Full Text
- View/download PDF
31. Treatment of allosensitized patients receiving allogeneic transplantation.
- Author
-
Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, and Cao K
- Subjects
- Female, Humans, Male, Middle Aged, Rituximab therapeutic use, Tissue Donors, Transplantation, Homologous, HLA Antigens, Hematopoietic Stem Cell Transplantation
- Abstract
Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no other donor options and/or are in need to proceed urgently to transplantation. We studied a multimodality treatment with alternate-day plasma exchange (PE), rituximab, intravenous γ globulin (IVIg) and an irradiated donor buffy coat for patients with DSAs at 2 institutions. Thirty-seven patients with a median age of 51 years were treated with this desensitization protocol. Treatment outcomes were compared with a control group of HaploSCT patients without DSAs (n = 345). The majority of patients in the DSA group were female (83.8% vs 37.1% in controls, P < .001) and received stem cells from a child as the donor (67.6% vs 44.1%, P = .002). Mean DSA level before and after desensitization was 10 198 and 5937 mean fluorescence intensity (MFI), respectively, with mean differences of 4030 MFI. Fourteen of 30 tested patients (46.7%) had C1q positivity, while 8 of 29 tested patients (27.6%) remained positive after desensitization. In multivariable analysis, patients with initial DSA > 20 000 MFI and persistent positive C1q after desensitization had a significantly lower engraftment rate, which resulted in significantly higher non-relapse mortality and worse overall survival (OS) than controls, whereas graft outcome and survival of patients with initial DSA < 20 000 MFI and those with negative C1q after treatment were comparable with controls. In conclusion, treatment with PE, rituximab, IVIg, and donor buffy coat is effective in promoting engraftment in patients with DSAs ≤20 000 MFI., (© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
- Author
-
Jeyakumar N, Aldoss I, Yang D, Mokhtari S, Gendzekhadze K, Khaled S, O'Donnell M, Palmer J, Song JY, Marcucci G, Stein AS, Forman SJ, Pullarkat VA, Chen W, Wu X, and Nakamura R
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Retrospective Studies, Antibodies, Bispecific administration & dosage, Antibodies, Bispecific adverse effects, Cytokine Release Syndrome blood, Cytokine Release Syndrome chemically induced, Cytokine Release Syndrome genetics, Interleukin-17 blood, Interleukin-17 genetics, Interleukin-2 blood, Interleukin-2 genetics, Polymorphism, Single Nucleotide, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Blinatumomab is a bispecific T cell-engaging antibody approved for treatment of relapsed/refractory (r/r) ALL, with 40%-50% complete response (CR)/CR with incomplete count recovery (CRi). Cytokine release syndrome (CRS) as a major adverse effect after blinatumomab therapy. Here, we evaluated the possible association between single-nucleotide polymorphisms (SNPs) in cytokine genes, disease response, and CRS in r/r ALL patients who received blinatumomab between 2012 and 2017 at our center (n = 66), using patients' archived DNA samples. With a median duration of 9.5 months (range: 1-37), 37 patients (56.1%) achieved CR/CRi, 54 (81.8%) experienced CRS (G1: n = 35, G2: n = 14, G3: n = 5), and 9 (13.6%) developed neurotoxicity. By multivariable analysis, after adjusting for high disease burden, one SNP on IL2 (rs2069762), odds ratio (OR) = 0.074 (95% CI: NE-0.43, P = .01) and one SNP on IL17A (rs4711998), OR = 0.28 (95% CI: 0.078-0.92, P = .034) were independently associated with CR/CRi. None of the analyzed SNPs were associated with CRS. To our knowledge, this is the first study demonstrating a possible association between treatment response to blinatumomab and SNPs. Our hypothesis-generated data suggest a potential role for IL-17 and IL-2 in blinatumomab response and justify a larger confirmatory study, which may lead to personalized blinatumomab immunotherapy for B-ALL., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
33. Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation.
- Author
-
Dubreuil L, Maniangou B, Chevallier P, Quéméner A, Legrand N, Béné MC, Willem C, David G, Alizadeh M, Makanga DR, Cesbron A, Gendzekhadze K, Gagne K, and Retière C
- Abstract
We have recently shown a broad disparity of Natural Killer (NK) cell responses against leukemia highlighting good and bad responders resting on the Killer cell Immunoglobulin-like Receptors (KIR) and HLA genetics. In this study, we deeply studied KIR2D allele expression, HLA-C recognition and functional effect on NK cells in 108 blood donors in combining high-resolution KIR allele typing and multicolor flow cytometry. The KIR2DL1*003 allotype is associated with centromeric (cen) AA motif and confers the highest NK cell frequency, expression level and strength of KIR/HLA-C interactions compared to the KIR2DL1*002 and KIR2DL1*004 allotypes respectively associated with cenAB and BB motifs. KIR2DL2*001 and *003 allotypes negatively affect the frequency of KIR2DL1
+ and KIR2DL3+ NK cells. Altogether, our data suggest that cenAA individuals display more efficient KIR2DL alleles (L1*003 and L3*001) to mount a consistent frequency of KIR2DL+ NK cells and to confer an effective NK cell responsiveness. The transposition of our in vitro observations in the T-replete haplo-identical HSCT context led us to observe that cenAA HSC grafts limit significantly the incidence of relapse in patients with myeloid diseases after T-replete haplo-identical HSCT. As NK cells are crucial in HSCT reconstitution, one could expect that the consideration of KIR2DL1/2/3 allelic polymorphism could help to refine scores used for HSC donor selection.- Published
- 2020
- Full Text
- View/download PDF
34. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
- Author
-
Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, Gendzekhadze K, Peterlin P, Garnier A, Le Bourgeois A, Béné MC, Chevallier P, and Retière C
- Subjects
- Adult, Aged, CD3 Complex metabolism, Female, Graft vs Host Disease metabolism, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Killer Cells, Natural metabolism, Male, Middle Aged, Peripheral Blood Stem Cells metabolism, Retrospective Studies, Stem Cell Transplantation adverse effects, T-Lymphocytes metabolism, Transplantation Conditioning adverse effects, Transplantation, Haploidentical adverse effects, Transplantation, Homologous adverse effects, Young Adult, Antilymphocyte Serum therapeutic use, Cyclophosphamide therapeutic use, Graft vs Host Disease drug therapy, Immunosuppressive Agents therapeutic use, Killer Cells, Natural drug effects, Peripheral Blood Stem Cells drug effects, T-Lymphocytes drug effects
- Abstract
A higher incidence of graft-versus-host disease (GVHD) has been observed after haploidentical hematopoietic stem cell transplantation (h-HSCT) with posttransplant cyclophosphamide (PTCY) using peripheral blood stem cells (PBSC) as a source of graft. Moreover, combining PTCY with antithymocyte globulin (ATG) may help to reduce GVHD incidence. In this study, early immune reconstitution, especially of T and NK cell compartments, was compared after both types of transplant (PTCY versus PTCY + ATG) investigate their influence on patient outcomes. This retrospective study included 58 adults who received a reduced intensity conditioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl + PTCY ( n = 32) or PTCY + ATG ( n = 26) as GVHD prophylaxis. Both groups shared similar characteristics except for the median number of CD3
+ T cells infused, significantly higher for PTCY + ATG patients. Blood samples from all patients were collected three times a week from day 0 until day 30 then at day 60 and day 90/100 to evaluate T and NK cells reconstitution by flow cytometry. The results show that PTCY + ATG versus PTCY alone significantly limits the occurrence of acute grade 2-4 GVHD after reduced intensity conditioning PBSC h-HSCT, perhaps because of the combined effect of T and NK cell reconstitution. Indeed, although a slower T cell reconstitution with PTCY + ATG may limit GVHD occurrence, the quicker reconstitution of some NK cell subtypes may help with avoiding relapse. Larger prospective studies are needed to better determine which NK cell subsets may influence the incidence of relapse after h-HSCT and optimize donor selection., (Copyright © 2020 by The American Association of Immunologists, Inc.)- Published
- 2020
- Full Text
- View/download PDF
35. Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia.
- Author
-
Makanga DR, Da Rin de Lorenzo F, David G, Willem C, Dubreuil L, Legrand N, Guillaume T, Peterlin P, Lebourgeois A, Béné MC, Garnier A, Chevallier P, Gendzekhadze K, Cesbron A, Gagne K, Clemenceau B, and Retière C
- Abstract
Natural killer (NK) cells are key cytotoxic effectors against malignant cells. Polygenic and polymorphic Killer cell Immunoglobulin-like Receptor (KIR) and HLA genes participate in the structural and functional formation of the NK cell repertoire. In this study, we extensively investigated the anti-leukemic potential of NK cell subsets, taking into account these genetic parameters and cytomegalovirus (CMV) status. Hierarchical clustering analysis of NK cell subsets based on NKG2A, KIR, CD57 and NKG2C markers from 68 blood donors identified donor clusters characterized by a specific phenotypic NK cell repertoire linked to a particular immunogenetic KIR and HLA profile and CMV status. On the functional side, acute lymphoblastic leukemia (ALL) was better recognized by NK cells than acute myeloid leukemia (AML). However, a broad inter-individual disparity of NK cell responses exists against the same leukemic target, highlighting bad and good NK responders. The most effective NK cell subsets against different ALLs expressed NKG2A and represented the most frequent subset in the NK cell repertoire. In contrast, minority CD57
+ or/and KIR+ NK cell subsets were more efficient against AML. Overall, our data may help to optimize the selection of hematopoietic stem cell donors on the basis of immunogenetic KIR/HLA for ALL patients and identify the best NK cell candidates in immunotherapy for AML.- Published
- 2020
- Full Text
- View/download PDF
36. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
- Author
-
Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, and Nakamura R
- Subjects
- Chronic Disease, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease epidemiology, Hematologic Neoplasms therapy, Histocompatibility Testing methods, Humans, Immunosuppressive Agents therapeutic use, Incidence, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate trends, Transplantation Conditioning, Transplantation, Homologous, United States epidemiology, Forecasting, Graft vs Host Disease prevention & control, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation adverse effects, Sirolimus therapeutic use, Tacrolimus therapeutic use, Unrelated Donors
- Abstract
Background: While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term outcome in matched (MUD) and mismatched unrelated donor (mMUD) setting is not well defined., Methods: Herein, we evaluated a consecutive case-series of 482 patients who underwent unrelated donor HCT (2005-2013) with T/S-based GvHD prophylaxis., Results: With a median follow-up of 6.2 years (range = 2.4-11.3), the 5-year overall survival (OS) and relapse/progression-free survival were 47.5% (95% confidence interval [CI]: 43.0-52.0) and 43.6% (95% CI: 39.1-48.1), respectively; and the 5-year cumulative incidence of nonrelapse mortality (NRM) and relapse were 24.9%, and 31.5%, respectively. In this cohort, mMUD was associated with worse OS (39.0% versus 50.7% at 5 y; P = 0.034), primarily due to greater risk of NRM (33.5% versus 21.7%; P = 0.038). While rates of relapse, acute (II-IV or III-IV) or chronic GvHD (limited or extensive) were not different, death caused by chronic GvHD (20.8% versus 12.8%; P = 0.022) and infection (33.0% versus 18.1%; P < 0.01) were significantly greater in mMUD. In multivariable analysis, high-risk disease (hazard ratio [HR] = 2.21, 95% CI: 1.16-4.23; P < 0.01) and mMUD (HR = 1.55, 95% CI: 1.15-2.08; P = 0.004) were independent predictive factors for OS., Conclusions: T/S-based GvHD prophylaxis is an effective and acceptable GvHD prophylactic regimen. However, survival after mMUD remained poor, possibly related to the severity of chronic GvHD.
- Published
- 2020
- Full Text
- View/download PDF
37. Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation.
- Author
-
Malki MMA, Gendzekhadze K, Stiller T, Mokhtari S, Karanes C, Parker P, Snyder D, Forman SJ, Nakamura R, and Nademanee A
- Subjects
- HLA-DP beta-Chains, Histocompatibility Testing, Humans, Neoplasm Recurrence, Local, Retrospective Studies, Transplantation Conditioning, Unrelated Donors, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation
- Abstract
A mismatch at HLA-DPB1 locus is associated with higher acute GVHD and lower relapse rate after myeloablative (MAC) allogeneic hematopoietic cell transplantation (alloHCT). Also, in MAC setting, mismatch permissiveness and expression level impact alloHCT outcomes. However, in reduced intensity conditioning (RIC), DP mismatch effect on transplant outcomes is unknown. We retrospectively evaluated DP mismatch influence (number, permissiveness, and expression) on HCT outcomes in 310 patients with high-resolution typing (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1), who underwent RIC HCT. By multivariable analysis, 11/12 had better overall survival (OS) and relapse vs. 12/12 (HR = 1.61 and 2.02; p = 0.04 and 0.01, respectively) and better OS vs. 10/12 (HR = 1.68; p = 0.02). Within the 11/12, nonpermissive (NoPR) mismatch was associated with higher risk of grade II-IV acute GVHD (HR = 1.97; p = 0.005) and nonrelapse mortality (HR = 2.13; p = 0.02) vs. permissive (PR). Grouping 11/12 based on the DP expression conferred higher mortality (HR = 3.78; p = 0.003) when low expressers received a graft from high expressers (AG) vs. low expressers (AA). Better OS was achieved in PR 11/12, when expression was low in patient and donor (AA) vs. all other combinations. Therefore, in RIC HCT, a single-DP mismatch has a protective role, especially in permissive setting, when donor and recipient are low expressers.
- Published
- 2020
- Full Text
- View/download PDF
38. The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.
- Author
-
Zhong C, Gragert L, Maiers M, Hill BT, Garcia-Gomez J, Gendzekhadze K, Senitzer D, Song J, Weisenburger D, Goldstein L, and Wang SS
- Subjects
- Adult, Clinical Decision-Making, Diagnosis, Differential, Disease Management, Female, Haplotypes, Hematopoietic Stem Cell Transplantation, Humans, Leupeptins, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Genetic Association Studies, Genetic Predisposition to Disease, HLA Antigens genetics, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin genetics
- Abstract
Several studies have implicated HLA in non-Hodgkin lymphoma (NHL) subtype etiology. However, NHL patients indicated for stem cell transplants are underrepresented in these reports. We therefore evaluated the association between HLA and NHL subtypes among a transplant-indicated population. One thousand three hundred and sixty-six NHL patients HLA-typed and indicated for transplant at the City of Hope National Medical Center (Duarte, CA) were compared to 10,271 prospective donors. Odds ratios and 95% confidence intervals were calculated for HLA haplotype and alleles, adjusted for sex and age. The HLA-A*0201∼C*0602∼B*1302∼DRB1*0701∼DQB1*0201 haplotype was significantly associated with follicular lymphoma (FL) risk among Caucasians. Several haplotypes were associated with diffuse large B-cell lymphoma (DLBCL) risk among Caucasians, including the previously implicated DLBCL risk loci, HLA-B*0801 . The HLA-A*0101 allele was also observed to be associated with mantle cell lymphoma (MCL) risk. Our results support the association between previously reported susceptibility loci and FL and suggest potentially new DLBCL and MCL risk loci.
- Published
- 2019
- Full Text
- View/download PDF
39. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
- Author
-
Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, and Stein A
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Cytomegalovirus Infections virology, Disease-Free Survival, Female, Genotype, Humans, Male, Middle Aged, Recurrence, Retrospective Studies, Risk Factors, Cytomegalovirus Infections complications, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Receptors, KIR genetics, Unrelated Donors, Virus Activation physiology
- Abstract
Multiple retrospective studies have demonstrated an association between cytomegalovirus (CMV) reactivation and reduced risk of AML relapse. However, the potential mechanism explaining this association remains elusive. We investigated a homogeneous cohort of 288 adult patients with AML in remission who received allogeneic hematopoietic stem cell transplantation (HCT) from matched sibling/unrelated donors between 1995 and 2011. The 5-year cumulative incidence of relapse was greater in patients without CMV reactivation compared with those with reactivation (30.2% vs. 12.1%, p = 0.001) in a landmark analysis. In multivariate analyses CMV reactivation was independently associated with reduced relapse risk (HR: 0.49 [0.25-0.95], p = 0.036) and increased non-relapse mortality (26.5% vs. 13.1%, p = 0.002) resulting in similar 5-year overall survival (64.5% vs. 59.1%, p = 0.8). In further subgroup analyses the protective effect of CMV reactivation was significant in patients who received HCT from donors with KIR Bx compared to KIR AA (11.7% vs. 29.5%, p = 0.01). Likewise, the protective effect of CMV reactivation was more significant when the donors had 2DS1 activating KIR (11.5% vs. 30.7%, p = 0.05) compared with those without 2DS1 (14.3% vs. 27.5%, p = 0.12). Our data independently confirmed the association between CMV reactivation and AML relapse, suggesting the involvement of donor KIR genotypes and NK cell-mediated graft-versus-leukemia effect., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
40. HLA alleles and haplotypes observed in 263 US families.
- Author
-
Osoegawa K, Mallempati KC, Gangavarapu S, Oki A, Gendzekhadze K, Marino SR, Brown NK, Bettinotti MP, Weimer ET, Montero-Martín G, Creary LE, Vayntrub TA, Chang CJ, Askar M, Mack SJ, and Fernández-Viña MA
- Subjects
- Base Sequence genetics, Child, Ethnicity genetics, Exons genetics, Gene Frequency genetics, High-Throughput Nucleotide Sequencing, Histocompatibility Testing, Humans, Introns genetics, Linkage Disequilibrium genetics, Pedigree, Software, United States, Untranslated Regions genetics, Alleles, HLA Antigens genetics, Haplotypes genetics, Nuclear Family
- Abstract
The 17th International HLA and Immunogenetics Workshop (IHIW) conducted a project entitled "The Study of Haplotypes in Families by NGS HLA". We investigated the HLA haplotypes of 1017 subjects in 263 nuclear families sourced from five US clinical immunogenetics laboratories, primarily as part of the evaluation of related donor candidates for hematopoietic stem cell and solid organ transplantation. The parents in these families belonged to five broad groups - African (72 parents), Asian (115), European (210), Hispanic (118) and "Other" (11). High-resolution HLA genotypes were generated for each subject using next-generation sequencing (NGS) HLA typing systems. We identified the HLA haplotypes in each family using HaplObserve, software that builds haplotypes in families by reviewing HLA allele segregation from parents to children. We calculated haplotype frequencies within each broad group, by treating the parents in each family as unrelated individuals. We also calculated standard measures of global linkage disequilibrium (LD) and conditional asymmetric LD for each ethnic group, and used untruncated and two-field allele names to investigate LD patterns. Finally we demonstrated the utility of consensus DNA sequences in identifying novel variants, confirming them using HLA allele segregation at the DNA sequence level., (Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop.
- Author
-
Creary LE, Guerra SG, Chong W, Brown CJ, Turner TR, Robinson J, Bultitude WP, Mayor NP, Marsh SGE, Saito K, Lam K, Duke JL, Mosbruger TL, Ferriola D, Monos D, Willis A, Askar M, Fischer G, Saw CL, Ragoussis J, Petrek M, Serra-Pagés C, Juan M, Stavropoulos-Giokas C, Dinou A, Ameen R, Al Shemmari S, Spierings E, Gendzekhadze K, Morris GP, Zhang Q, Kashi Z, Hsu S, Gangavarapu S, Mallempati KC, Yamamoto F, Osoegawa K, Vayntrub T, Chang CJ, Hansen JA, and Fernández-Viňa MA
- Subjects
- Alleles, Cell Line, Transformed, Cell Transformation, Viral, Data Accuracy, Exons genetics, Genetic Loci, Genetic Variation, Genotype, Haplotypes genetics, High-Throughput Nucleotide Sequencing methods, Histocompatibility, Homozygote, Humans, Sequence Analysis, DNA methods, Single-Blind Method, B-Lymphocytes virology, HLA Antigens genetics, Herpesvirus 4, Human immunology, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class II genetics, Histocompatibility Testing methods
- Abstract
Extended molecular characterization of HLA genes in the IHWG reference B-lymphoblastoid cell lines (B-LCLs) was one of the major goals for the 17th International HLA and Immunogenetics Workshop (IHIW). Although reference B-LCLs have been examined extensively in previous workshops complete high-resolution typing was not completed for all the classical class I and class II HLA genes. To address this, we conducted a single-blind study where select panels of B-LCL genomic DNA samples were distributed to multiple laboratories for HLA genotyping by next-generation sequencing methods. Identical cell panels comprised of 24 and 346 samples were distributed and typed by at least four laboratories in order to derive accurate consensus HLA genotypes. Overall concordance rates calculated at both 2- and 4-field allele-level resolutions ranged from 90.4% to 100%. Concordance for the class I genes ranged from 91.7 to 100%, whereas concordance for class II genes was variable; the lowest observed at HLA-DRB3 (84.2%). At the maximum allele-resolution 78 B-LCLs were defined as homozygous for all 11 loci. We identified 11 novel exon polymorphisms in the entire cell panel. A comparison of the B-LCLs NGS HLA genotypes with the HLA genotypes catalogued in the IPD-IMGT/HLA Database Cell Repository, revealed an overall allele match at 68.4%. Typing discrepancies between the two datasets were mostly due to the lower-resolution historical typing methods resulting in incomplete HLA genotypes for some samples listed in the IPD-IMGT/HLA Database Cell Repository. Our approach of multiple-laboratory NGS HLA typing of the B-LCLs has provided accurate genotyping data. The data generated by the tremendous collaborative efforts of the 17th IHIW participants is useful for updating the current cell and sequence databases and will be a valuable resource for future studies., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
42. Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop.
- Author
-
Osoegawa K, Vayntrub TA, Wenda S, De Santis D, Barsakis K, Ivanova M, Hsu S, Barone J, Holdsworth R, Diviney M, Askar M, Willis A, Railton D, Laflin S, Gendzekhadze K, Oki A, Sacchi N, Mazzocco M, Andreani M, Ameen R, Stavropoulos-Giokas C, Dinou A, Torres M, Dos Santos Francisco R, Serra-Pages C, Goodridge D, Balladares S, Bettinotti MP, Iglehart B, Kashi Z, Martin R, Saw CL, Ragoussis J, Downing J, Navarrete C, Chong W, Saito K, Petrek M, Tokic S, Padros K, Beatriz Rodriguez M, Zakharova V, Shragina O, Marino SR, Brown NK, Shiina T, Suzuki S, Spierings E, Zhang Q, Yin Y, Morris GP, Hernandez A, Ruiz P, Khor SS, Tokunaga K, Geretz A, Thomas R, Yamamoto F, Mallempati KC, Gangavarapu S, Kanga U, Tyagi S, Marsh SGE, Bultitude WP, Liu X, Cao D, Penning M, Hurley CK, Cesbron A, Mueller C, Mytilineos J, Weimer ET, Bengtsson M, Fischer G, Hansen JA, Chang CJ, Mack SJ, Creary LE, and Fernandez-Viña MA
- Subjects
- Alleles, Consensus Development Conferences as Topic, Humans, International Cooperation, Pilot Projects, Quality Control, Software, Genotype, HLA Antigens genetics, High-Throughput Nucleotide Sequencing methods, Histocompatibility Testing methods, Immunogenetics
- Abstract
The 17th International HLA and Immunogenetics Workshop (IHIW) organizers conducted a Pilot Study (PS) in which 13 laboratories (15 groups) participated to assess the performance of the various sequencing library preparation protocols, NGS platforms and software in use prior to the workshop. The organizers sent 50 cell lines to each of the 15 groups, scored the 15 independently generated sets of NGS HLA genotyping data, and generated "consensus" HLA genotypes for each of the 50 cell lines. Proficiency Testing (PT) was subsequently organized using four sets of 24 cell lines, selected from 48 of 50 PS cell lines, to validate the quality of NGS HLA typing data from the 34 participating IHIW laboratories. Completion of the PT program with a minimum score of 95% concordance at the HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 loci satisfied the requirements to submit NGS HLA typing data for the 17th IHIW projects. Together, these PS and PT efforts constituted the 17th IHIW Quality Control project. Overall PT concordance rates for HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-DRB4 and HLA-DRB5 were 98.1%, 97.0% and 98.1%, 99.0%, 98.6%, 98.8%, 97.6%, 96.0%, 99.1%, 90.0% and 91.7%, respectively. Across all loci, the majority of the discordance was due to allele dropout. The high cost of NGS HLA genotyping per experiment likely prevented the retyping of initially failed HLA loci. Despite the high HLA genotype concordance rates of the software, there remains room for improvement in the assembly of more accurate consensus DNA sequences by NGS HLA genotyping software., (Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
43. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
- Author
-
Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Malki MMA, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, and Nakamura R
- Subjects
- Female, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes chemically induced, Myelodysplastic Syndromes mortality, Transplantation, Homologous, Myelodysplastic Syndromes therapy, Stem Cell Transplantation methods, Tumor Suppressor Protein p53 genetics
- Abstract
Therapy-related myelodysplastic syndrome is a long-term complication of cancer treatment in patients receiving cytotoxic therapy, characterized by high-risk genetics and poor outcomes. Allogeneic hematopoietic cell transplantation is the only potential cure for this disease, but the prognostic impact of pre-transplant genetics and clinical features has not yet been fully characterized. We report here the genetic and clinical characteristics and outcomes of a relatively large cohort of patients with therapy-related myelodysplastic syndrome (n=67) who underwent allogeneic transplantation, comparing these patients to similarly treated patients with de novo disease (n=199). The 5-year overall survival was not different between patients with therapy-related and de novo disease (49.9% versus 53.9%; P =0.61) despite a higher proportion of individuals with an Intermediate-2/High International Prognostic Scoring System classification (59.7% versus 43.7%; P =0.003) and high-risk karyotypes (61.2% versus 30.7%; P<0.01) among the patients with therapy-related disease. In mutational analysis, TP53 alteration was the most common abnormality in patients with therapy-related disease (n=18: 30%). Interestingly, the presence of mutations in TP53 or in any other of the high-risk genes ( EZH2 , ETV6 , RUNX1 , ASXL1 : n=29: 48%) did not significantly affect either overall survival or relapse-free survival. Allogeneic stem-cell transplantation is, therefore, a curative treatment for patients with therapy-related myelodysplastic syndrome, conferring a similar long-term survival to that of patients with de novo disease despite higher-risk features. While TP53 alteration was the most common mutation in therapy-related myelodysplastic syndrome, the finding was not detrimental in our case-series., (Copyright© 2017 Ferrata Storti Foundation.)
- Published
- 2017
- Full Text
- View/download PDF
44. Protective effect of the KIR2DS1 gene in atopic dermatitis.
- Author
-
Niepiekło-Miniewska W, Majorczyk E, Matusiak L, Gendzekhadze K, Nowak I, Narbutt J, Lesiak A, Kuna P, Ponińska J, Pietkiewicz-Sworowska A, Samoliński B, Płoski R, Szepietowski JC, Senitzer D, and Kuśnierczyk P
- Subjects
- Adolescent, Adult, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Dermatitis, Atopic prevention & control, Epitopes immunology, Female, HLA Antigens immunology, Humans, Linkage Disequilibrium, Male, Middle Aged, Young Adult, Dermatitis, Atopic genetics, Receptors, KIR genetics
- Abstract
Atopic dermatitis (AD) is a common skin disease of complex etiology including affected humoral and cellular immune responses. The role of NK cells in development of this disease has been recently postulated, but is still poorly documented. The current study was undertaken to determine the impact of genes for the most polymorphic NK cell receptors, known as killer cell immunoglobulin-like receptors (KIRs), on the development of AD. We compared 240 patients suffering from AD with 570 healthy controls. Frequencies of the great majority of KIR genes did not differ between patients and controls, except for KIR2DS1, whose frequency was significantly (OR=0.629, CI95% (0.45; 0.87), pcorr=0.0454) lower in patients than in controls. These results were confirmed in a second cohort of 201 patients. When both patient groups were combined and compared to the control group, the result for KIR2DS1 achieved even higher significance (OR=0.658, CI95% (0.5; 0.86), pcorr=0.0158). To the best of our knowledge, this is the first report on KIR gene contribution to AD, and to allergy in general., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
45. Chimerism testing by quantitative PCR using Indel markers.
- Author
-
Gendzekhadze K, Gaidulis L, and Senitzer D
- Subjects
- Graft Rejection immunology, Hematopoietic Stem Cell Transplantation, Humans, INDEL Mutation genetics, Polymerase Chain Reaction methods, Tissue Donors, Transplantation, Homologous, Genetic Markers, Graft Rejection genetics, Molecular Biology methods, Transplantation Chimera
- Abstract
Engraftment monitoring is critical for patients after Hematopoietic Stem Cell Transplantation (HSCT). Complete donor chimerism is the goal; therefore, early detection of rejection and relapse is crucial for guiding the patient post HSCT treatment. Quantitative PCR for chimerism testing has been reported to be highly sensitive. In this chapter we discuss the quantitative PCR (qPCR) method using 34 Indel (Insertion and Deletion) genetic markers spread over 20 different chromosomes.
- Published
- 2013
- Full Text
- View/download PDF
46. KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).
- Author
-
Gallez-Hawkins GM, Li X, Franck AE, Gendzekhadze K, Nakamura R, Forman SJ, Senitzer D, and Zaia JA
- Subjects
- Cell Line, CpG Islands, Gene Expression Regulation, Gene Order, Hematopoietic Stem Cell Transplantation, Humans, Leukocytes, Mononuclear metabolism, Tissue Donors, DNA Methylation, Promoter Regions, Genetic, Receptors, KIR genetics
- Abstract
The killer cell Ig-like receptor (KIR)-MHC class I pathway is an integral part of natural killer cell immunity, and its role in host protection from both cancer and infection is important. In addition, we have shown elevated KIR2DS2 and 2DS4 expression in PBMCs of patients undergoing hematopoietic cell transplantation (HCT) [1]. Since all inhibitory KIR promoters are known to be heavily methylated, the question asked here is how and when KIR2DS2 and 2DS4 promoters had changed their methylation profile in association with HCT. Genomic DNA, extracted from 20 KIR2DS2/4+ donor and recipient cells, was treated with sodium bisulfate that will modify the unmethylated cytosine into uracil. Sequencing chromatographs were examined for C/T double peak indicative of base conversion. A CpG island in KIR2DS2 promoter spans from -160 to +26 with six cytosine sites. In contrast, the KIR2DS4 promoter CpG island contains three cytosine sites. The noted increase of unmethylated sites was associated with increased KIR expression as measured by mRNA-cDNA Q-PCR. In addition, the frequency of unmethylated sites in the CpG island was increased after HCT. The mechanism through which hypomethylation occurs after HCT is not known but it suggests a linkage to NK clonal expansion during the process of NK education in response to transplant therapy or viral infection., (Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
47. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.
- Author
-
Gallez-Hawkins GM, Franck AE, Li X, Thao L, Oki A, Gendzekhadze K, Dagis A, Palmer J, Nakamura R, Forman SJ, Senitzer D, and Zaia JA
- Subjects
- Adult, Cytomegalovirus Infections etiology, Cytomegalovirus Infections metabolism, Female, Humans, Male, RNA, Messenger biosynthesis, RNA, Messenger genetics, Receptors, KIR genetics, Transplantation, Homologous adverse effects, Virus Activation, Cytomegalovirus Infections genetics, Hematopoietic Stem Cell Transplantation adverse effects, Receptors, KIR biosynthesis
- Abstract
The important role of activating killer immunoglobulin-like receptors (KIRs) in protecting against cytomegalovirus (CMV) reactivation has been described previously in patients undergoing hematopoietic cell transplantation (HCT). More specifically, the presence of multiple activating KIRs and the presence of at least KIR2DS2 and KIR2DS4 in the donor genotype identified a group of HCT patients at low risk for CMV reactivation. However, CMV infection still occurs in patients with the KIR protective genotype, and the question has been raised as to whether this is related to the lack of KIR expression. In this report, expression of the KIR2DS2 and KIR2DS4 genes, as measured by mRNA-based quantitative polymerase chain reaction in both the donor cells and the HCT recipient cells, was studied relative to CMV reactivation. In the control samples from healthy donors, the median range for KIR2DS2 and KIR2DS4 expression was low, with 35% of donors considered null-expressers. Interestingly, KIR2DS2 and KIR2DS4 expression was elevated after HCT compared with donor expression before HCT, and was significantly elevated in CMV viremic compared with CMV nonviremic HCT recipients. The CMV seropositivity of donors was not associated with activating KIR expression, and donor null expression in those with the KIR2DS2 or KIR2DS4 genotype was not predictive for CMV reactivation in the recipient. After controlling for other transplant factors, including donor type (sibling or unrelated), transplant source (bone marrow or peripheral blood stem cells), and acute GVHD grade, regression analysis of elevated KIR gene expression found an association for both KIR2DS2 and KIR2DS4, with a 7-fold increase in risk for CMV reactivation. We speculate that the elevated activating KIR expression in CMV-viremic HCT recipients is either coincidental with factors that activate CMV or is initiated by CMV or cellular processes responsive to such CMV infection reactivation., (Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
48. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands.
- Author
-
Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z, and Parham P
- Subjects
- Alleles, Epitopes immunology, Haplotypes, Humans, Ligands, Molecular Sequence Data, Mutation genetics, Selection, Genetic, Evolution, Molecular, Genetic Variation, HLA-C Antigens genetics, Indians, South American genetics, Receptors, KIR2DL3 genetics
- Abstract
Natural killer (NK) cells contribute to immunity and reproduction. Guiding these functions, and NK cell education, are killer cell Ig-like receptors (KIR), NK cell receptors that recognize HLA class I. In most human populations, these highly polymorphic receptors and ligands combine with extraordinary diversity. To assess how much of this diversity is necessary, we studied KIR and HLA class I at high resolution in the Yucpa, a small South Amerindian population that survived an approximate 15,000-year history of population bottleneck and epidemic infection, including recent viral hepatitis. The Yucpa retain the three major HLA epitopes recognized by KIR. Through balancing selection on a few divergent haplotypes the Yucpa maintain much of the KIR variation found worldwide. HLA-C*07, the strongest educator of C1-specific NK cells, has reached unusually high frequency in the Yucpa. Concomitantly, weaker variants of the C1 receptor, KIR2DL3, were selected and have largely replaced the form of KIR2DL3 brought by the original migrants from Asia. HLA-C1 and KIR2DL3 homozygosity has previously been correlated with resistance to viral hepatitis. Selection of weaker forms of KIR2DL3 in the Yucpa can be seen as compensation for the high frequency of the potent HLA-C*07 ligand. This study provides an estimate of the minimal KIR-HLA system essential for long-term survival of a human population. That it contains all functional elements of KIR diversity worldwide, attests to the competitive advantage it provides, not only for surviving epidemic infections, but also for rebuilding populations once infection has passed.
- Published
- 2009
- Full Text
- View/download PDF
49. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
- Author
-
Korbel DS, Norman PJ, Newman KC, Horowitz A, Gendzekhadze K, Parham P, and Riley EM
- Subjects
- CD56 Antigen immunology, Cytokines immunology, Flow Cytometry, Genotype, Humans, Interferon-gamma immunology, Killer Cells, Natural metabolism, Lymphocyte Activation immunology, Lymphocyte Subsets metabolism, Antigens, Bacterial immunology, CD56 Antigen metabolism, Interferon-gamma biosynthesis, Killer Cells, Natural immunology, Lymphocyte Subsets immunology, Receptors, KIR immunology
- Abstract
IFN-gamma emanating from NK cells is an important component of innate defense against infection. In this study, we demonstrate that, following in vitro stimulation of human peripheral blood NK cells with a variety of microbial ligands, CD56(dim) as well as CD56(bright) NK cells contribute to the overall NK cell IFN-gamma response with, for most cell donors, IFN-gamma(+) CD56(dim) NK cells outnumbering IFN-gamma(+) CD56(bright) NK cells. We also observe that the magnitude of the human NK IFN-gamma response to microbial ligands varies between individuals; that the antimicrobial response of CD56(bright), but not CD56(dim), NK cells is highly correlated with that of myeloid accessory cells; and that the ratio of IFN-gamma(+) CD56(dim) to IFN-gamma(+) CD56(bright) NK cells following microbial stimulation differs between individuals but remains constant for a given donor over time. Furthermore, ratios of IFN-gamma(+) CD56(dim) to IFN-gamma(+) CD56(bright) NK cells for different microbial stimuli are highly correlated and the relative response of CD56(dim) and CD56(bright) NK cells is highly significantly associated with killer Ig-like receptor (KIR) genotype. These data reveal an influence of KIR genotype, possibly mediated via NK cell education, on the ability of NK cells to respond to nonviral infections and have implications for genetic regulation of susceptibility to infection in humans.
- Published
- 2009
- Full Text
- View/download PDF
50. Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes.
- Author
-
Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D, Graef T, McQueen KL, Guethlein LA, Carrington CV, Chandanayingyong D, Chang YH, Crespí C, Saruhan-Direskeneli G, Hameed K, Kamkamidze G, Koram KA, Layrisse Z, Matamoros N, Milà J, Park MH, Pitchappan RM, Ramdath DD, Shiau MY, Stephens HA, Struik S, Tyan D, Verity DH, Vaughan RW, Davis RW, Fraser PA, Riley EM, Ronaghi M, and Parham P
- Subjects
- Amino Acid Sequence, Cell Line, Evolution, Molecular, Humans, Models, Genetic, Molecular Sequence Data, Phenotype, Receptors, KIR genetics, Receptors, KIR3DL1 genetics, Alleles, Genetic Variation genetics, Haplotypes genetics, Meiosis genetics, Receptors, Natural Killer Cell genetics, Recombination, Genetic genetics
- Abstract
Natural killer (NK) cells contribute to the essential functions of innate immunity and reproduction. Various genes encode NK cell receptors that recognize the major histocompatibility complex (MHC) Class I molecules expressed by other cells. For primate NK cells, the killer-cell immunoglobulin-like receptors (KIR) are a variable and rapidly evolving family of MHC Class I receptors. Studied here is KIR3DL1/S1, which encodes receptors for highly polymorphic human HLA-A and -B and comprises three ancient allelic lineages that have been preserved by balancing selection throughout human evolution. While the 3DS1 lineage of activating receptors has been conserved, the two 3DL1 lineages of inhibitory receptors were diversified through inter-lineage recombination with each other and with 3DS1. Prominent targets for recombination were D0-domain polymorphisms, which modulate enhancer function, and dimorphism at position 283 in the D2 domain, which influences inhibitory function. In African populations, unequal crossing over between the 3DL1 and 3DL2 genes produced a deleted KIR haplotype in which the telomeric "half" was reduced to a single fusion gene with functional properties distinct from its 3DL1 and 3DL2 parents. Conversely, in Eurasian populations, duplication of the KIR3DL1/S1 locus by unequal crossing over has enabled individuals to carry and express alleles of all three KIR3DL1/S1 lineages. These results demonstrate how meiotic recombination combines with an ancient, preserved diversity to create new KIR phenotypes upon which natural selection acts. A consequence of such recombination is to blur the distinction between alleles and loci in the rapidly evolving human KIR gene family.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.